Filing summary: AVROBIO, Inc. — Q1 2022 Form 10-Q
Important entity discrepancy: The request names Tectonic Therapeutic, Inc., but the supplied filing is for AVROBIO, Inc. (Nasdaq: AVRO). This summary covers the supplied AVROBIO filing, for the quarter ended March 31, 2022.
Business context and reporting period
AVROBIO was a clinical-stage gene therapy company developing ex vivo lentiviral treatments for rare diseases. It reported five programs: cystinosis, Gaucher disease types 1 and 3, Hunter syndrome, and Pompe disease. It had no product revenue and relied on equity financing and debt to fund operations.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $19.3 million | $18.5 million |
| General and administrative expense | $10.2 million | $8.4 million |
| Total operating expenses | $29.4 million | $26.9 million |
| Net loss | $29.8 million; $0.68 per share | $26.9 million; $0.65 per share |
| Cash used in operating activities | $28.0 million | $27.3 million |
| Cash and cash equivalents at period end | $161.7 million | $189.6 million at December 31, 2021 |
| Total assets | $175.3 million | $203.8 million at December 31, 2021 |
| Total liabilities | $32.2 million | $34.4 million at December 31, 2021 |
| Note payable, net of discount | $15.0 million | $14.9 million at December 31, 2021 |
| Stockholders’ equity | $143.2 million | $169.5 million at December 31, 2021 |
Margins are not meaningful because the company had no revenue. Cash, cash equivalents and restricted cash totaled $162.2 million at March 31, 2022. The quarter’s net decrease in cash, cash equivalents and restricted cash was $27.9 million. Current assets were $170.9 million and current liabilities were $17.1 million.
Material changes versus the prior comparable period
- Net loss increased by $2.9 million year over year, reflecting higher operating expenses and $0.4 million of net interest and other expense, compared with $0.02 million of such expense in Q1 2021.
- R&D expense rose $0.7 million, primarily from increased clinical-trial consulting costs, partly offset by lower personnel costs. G&A expense rose $1.8 million, including higher facilities, professional and legal costs and workforce-reduction costs.
- Cash and cash equivalents declined $27.9 million from year-end 2021. Operating cash use was broadly similar to Q1 2021.
- Common shares outstanding were 43.696 million at March 31, 2022, compared with 43.652 million at year-end 2021.
Outlook, management commentary and notable items
- Management estimated that March 31 cash and cash equivalents would fund operating and capital needs into Q1 2024. The estimate depends on assumptions that may prove incorrect; the filing says additional capital will be needed to fund operations beyond that point.
- In January 2022, AVROBIO deprioritized AVR-RD-01 for Fabry disease after new Phase 2 data showed variable engraftment in five recently dosed patients and the program’s development timeline was expected to lengthen. Enrollment in the trial stopped. The company cited the development timeline and a challenging market and regulatory environment.
- Following the Fabry decision, the company announced an approximately 23% workforce reduction and broader cost-reduction plan. It recorded $1.369 million in restructuring expense; $1.324 million was paid in Q1, with approximately $45,000 accrued for expected payment in Q2.
- Management described these program plans: AVR-RD-04 cystinosis enrollment in the collaborator-sponsored Phase 1/2 trial was complete with six enrolled and five dosed; a company-sponsored trial was planned for 2023, subject to FDA interactions. Three patients had been dosed in the AVR-RD-02 Gaucher type 1 trial, with interim data planned in 2022. For Hunter syndrome, a UK trial application was expected in 2022 and an investigator-sponsored trial in 2023. The company planned regulatory discussions for Gaucher type 3 and Pompe, with potential trials in 2023. These are forward-looking plans, not assured outcomes.
- The SVB term loan had $15 million drawn and a stated maturity of October 1, 2026. It bears interest at the greater of prime plus 4.85% or 8.10%, with interest-only payments through November 2024 and an end-of-term charge equal to 9% of funded advances. Fabry deprioritization made $20 million of milestone-contingent borrowing unavailable; a further $15 million tranche requires lender approval. The loan is secured by substantially all assets other than intellectual property, which is subject to a negative pledge.
- Principal risks include continued losses and financing needs, clinical and regulatory uncertainty, gene-therapy safety and manufacturing risks, reliance on sole-source suppliers, COVID-19-related disruption, and restrictive loan covenants. No material litigation was reported. Management concluded disclosure controls were effective as of March 31, 2022.
Most important facts for investors to verify
- Confirm the intended issuer: the provided 10-Q is AVROBIO’s, not Tectonic Therapeutic’s.
- Assess the assumptions underlying the stated cash runway into Q1 2024 and the timing and terms of likely additional financing.
- Review subsequent clinical data and regulatory interactions for the continuing programs, including whether the Fabry engraftment issue has implications for other programs.
- Verify available borrowing under the SVB agreement, lender-consent requirements, covenants, interest costs and repayment obligations.
- Track restructuring execution, pipeline spending priorities, and potential dilution from future equity financing and outstanding equity awards.